Features of the Lantus® SoloSTAR® Pen
The Lantus® SoloSTAR® pen is designed for ease of use and has optimized
dose and injection features.
The Lantus® SoloSTAR® pen is:
- Prefilled with the #1 prescribed insulina
- Easy to learn, with only 6 straightforward steps1,2
- Easy to use―dial lets patients select the appropriate Lantus® dose from 1 to 80 units, 1 unit at a time1,2
- Easy to inject―dose cannot be dialed past the number of units left in the pen2,3
- It is important to keep the injection button pressed all the way
in and to slowly count to 10 before withdrawing needle from
skin. After a full injection, the number in the dose window will
return to zero. These steps help ensure that a full dose has been delivered
- Insulin dose dialed is the dose delivered4
- Dose dial returns to zero once dose has been delivered
- Portable5―once opened, the Lantus® SoloSTAR® pen can be used
for up to 28 days and should not be refrigerated. Instruct patients to keep the opened Lantus®
SoloSTAR® pen at room temperature (below 86°F). Lantus® SoloSTAR® pens
must be discarded 28 days after being opened6
More Lantus® units per prescription with Lantus® SoloSTAR® b,c
- 50% more insulin units for the same copay as a single vial and syringe on most managed care plans
- 1 box of 5 SoloSTAR® pensd = 1500 units vs 1 viale = 1000 units
Lantus® Savings Card Program
Qualifying Lantus® SoloSTAR® pen users pay no more than $25 per prescription, for up to 6 prescriptions, with the Lantus® Savings Card.*
Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)
Contraindications
Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.
Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Insulin regimens should
be modified cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur.
A reduction in the Lantus® dose may be required in patients with renal or hepatic
impairment.
Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and
close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients
taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Adverse Reactions
Other adverse reactions commonly associated with Lantus® are injection site
reaction, lipodystrophy, pruritus, and rash.
Important Safety Information for Lantus®
SoloSTAR®
Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.
Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and children (6 years and older) with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Lantus® SoloSTAR® is a disposable prefilled insulin pen.
Please click
here for Full Prescribing Information for Lantus®.
References:
- Hancu N, Czupryniak L, Genestin E, Sourij H. J Diabetes Sci Techol, 2011; 5(5):1224-1234
- Data on file, Sanofi U.S. LLC.
- Clarke A, Spollett G. Expert Opin Drug Deliv. 2007;4(2):165-174.
- Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz
M. Curr Med Res Opin. 2010;26(4):901-905.
- Haak T, Edelman S. Walter C, et al. Clin Ther. 2007;29(4):650-660.
- Lantus® Prescribing Information. April 2010.
Indications and Usage for Lantus® (insulin glargine
[rDNA origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and children (6 years and older) with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Important Safety Information for Lantus® (insulin
glargine [rDNA origin] injection)
Contraindications
Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.
Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Insulin regimens should
be modified cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Important Safety Information for Lantus® SoloSTAR®
Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.
Click here for additional Important Safety Information.
Online access to HCP
resources and information.